Acquisition-Related Contingent Consideration (Details)	12 Months Ended
	Dec. 31, 2012 USD ($)	Dec. 31, 2012 EUR (€)	Sep. 30, 2013 USD ($)	Sep. 30, 2010 USD ($)	Apr. 01, 2009 USD ($)	Apr. 01, 2009 EUR (€)	Mar. 31, 2009	Sep. 30, 2013 Norwood Secured Loan [Member] EUR (€)	Sep. 30, 2013 Norwood Secured Loan [Member] Payment One [Member] EUR (€)	Sep. 30, 2013 Norwood Secured Loan [Member] Payment Two [Member] EUR (€)	Sep. 30, 2013 Norwood Secured Loan [Member] Payment Three [Member] EUR (€)	Sep. 30, 2013 Norwood Secured Loan [Member] Payment Four [Member] EUR (€)	Dec. 31, 2012 As recorded on December 31, 2012 [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Dec. 31, 2012 As recorded on December 31, 2012 [Member] Royalties for RSV [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Dec. 31, 2012 As recorded on December 31, 2012 [Member] Royalties for HSV [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 Measurement Adjustment [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 Measurement Adjustment [Member] Royalties for RSV [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 Measurement Adjustment [Member] Royalties for HSV [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 As adjusted on June 30, 2013 [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 As adjusted on June 30, 2013 [Member] Royalties for RSV [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 As adjusted on June 30, 2013 [Member] Royalties for HSV [Member] Unobservable Inputs (Level 3) [Member] EUR (€)	Sep. 30, 2013 As adjusted on June 30, 2013 [Member] Royalties for Influenza Vaccines [Member] Unobservable Inputs (Level 3) [Member] EUR (€)
Business Acquisition, Contingent Consideration [Line Items]
Cash consideration paid for Bestewil						€ 5,000,000
Convertible redeemable note issued for Bestewil						2,500,000
Term of convertible redeemable note					36 months	36 months
Interest rate (in hundredths)							5.00%
Conversion price (in dollars per share)				$ 0.50	$ 0.80
Percentage of acquired entity's shares used as collateral for convertible debt (in hundredths)							33.30%
Numerator for conversion of debt	9,609,000
Fair value difference between original conversion price and shares actually issued		807,000
Debt instrument face amount			190,000					2,500,000
Debt amendment amount payable									521,000	517,000		1,576,000
Debt amendment principal payable									500,000	500,000		1,500,000
Debt amendment interest payable									21,000	17,000	51,000	76,000
Outstanding principal after first payment								2,000,000
Outstanding principal after second payment								1,500,000
Changes to the Company's acquisition-related contingent consideration [Abstract]
Fair value of the contingent consideration			$ 325,000										€ 6,533,000	€ 3,806,000	€ 2,727,000	€ 6,533,000	€ 3,806,000	€ 2,727,000	€ 241,000	€ 0	€ 0	€ 241,000